RxDoctor Payments Data

Christopher Short, MD

Family Medicine · Manhattan, KSNPI 1689024382

Payments from drug & device makers

$5,298in general payments, 2019–2025

Across 332 payments — averaging $15.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$753
  • Pfizer$631
  • Novo Nordisk$542
  • Lilly USA, LLC$351
  • AstraZeneca$328
  • Boehringer Ingelheim$218
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$5,24999%
  • Education$491%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,298 in reported general payments places this provider in the 85th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$236,488
Medicare patients
322
Services billed
20,780

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide27$28,465
JardianceEmpagliflozin30$24,643
EliquisApixaban41$22,026
OzempicSemaglutide17$19,490
AbrysvoRsv Vacc, Pref A And Pref B/Pf50$15,904
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$12,235
ShingrixVaricella-Zoster Ge/As01b/Pf49$10,860
JanuviaSitagliptin Phosphate16$9,518
FarxigaDapagliflozin Propanediol12$8,451
MyrbetriqMirabegron24$6,426
Modafinil22$2,033
Memantine Hcl23$1,726
Levothyroxine Sodium192$1,511
Boostrix TdapDiphth,pertuss(Acell),tet Vac20$1,380
Niacin ErNiacin12$1,103

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$631$37,93091 claims
Lilly USA, LLCMounjaro$351$28,46527 claims
Boehringer IngelheimJardiance$218$24,64330 claims
GSKTrelegy Ellipta, Shingrix$136$23,09562 claims
Novo NordiskOzempic$542$19,49017 claims
MerckJanuvia$153$9,51816 claims
AstraZenecaFarxiga$328$8,45112 claims
Astellas Pharma US IncMyrbetriq$46$6,42624 claims
AbbVieSynthroid$753$66014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Manhattan

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →